Delivery Order SPE2DB22D3301-SPE2DB25FZ0RX
- Not listed
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for VIMPAT 10 mg/ml solution in 200 ml quantities, with a ceiling value of $1,048.32. This is a firm fixed-price delivery order with an ultimate completion date of September 4, 2025, awarded on September 3, 2025. The award carries no set-aside designation and was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of VIMPAT 10 mg/mL solution in 200 mL quantities, valued at $1,844.01. This is a firm fixed-price delivery order with an ultimate completion date of September 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competitively awarded. VIMPAT (lacosamide) is an antiepileptic...
- The Defense Logistics Agency awarded a $1,455.99 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for VIMPAT 10 mg/mL Solution in 200 mL quantities. This firm fixed price order, with an ultimate completion date of August 4, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was awarded without a set-aside designation through competitive procurement, and performance will occur at the...
- The Defense Logistics Agency awarded a delivery order valued at $1,223.04 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of VIMPAT 10 mg/ml Solution in 200ml quantities. This firm fixed-price delivery order, which is non-set-aside and competitively awarded, will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. VIMPAT (lacosamide) is a prescription anticonvulsant medication used in the treatment of...
- The Defense Logistics Agency awarded a delivery order valued at $1,256.32 to AmerisourceBergen Drug Corp for VIMPAT 10 mg/ml solution in 200ml quantities. This non-competitive delivery order, issued on August 14, 2025, represents a firm fixed-price procurement executed under a child contract arrangement with an ultimate completion date of August 15, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for VIMPAT 10 mg/ml Solution 200ml, with a ceiling value of $1,136.96 under a firm fixed price contract type. The award was executed on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-set-aside competitive award is being performed at the contractor's facility in Conshohocken, Pennsylvania. VIMPAT (lacosamide) is an anticonvulsant medication used in the treatment of neurological...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of VIMPAT 100 mg tablets (60-count units) valued at $2,048.51. This firm fixed-price delivery order, which is expected to be completed by August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of VIMPAT 200 MG tablets in a quantity of 60 units, with a contract ceiling value of $1,089.82. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award through open competition. The contract has an ultimate completion date of July 28, 2025, and AmerisourceBergen will perform this work from its corporate office location in...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide VIMPAT 100 MG TABLET 60S for a total ceiling value of $1,484.97. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle for Amerisourcebergen to deliver...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VIMPAT 10 mg/ml solution in 200 ml containers, with a ceiling value of $1,105.15. It is a firm fixed-price delivery order contract with a period of performance ending on July 16, 2025. The contract is not set-aside for any specific business type. AmerisourceBergen Drug Corp holds a...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0RXDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for VIMPAT 10 mg/mL solution in 200 mL quantities, valued at $1,322.67, with a completion date of September 9, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor for medical procurement, particularly serving military and veteran healthcare systems through the DLA Medical Supply Chain. VIMPAT (lacosamide) is a neurological medication used in seizure management, consistent with the company's extensive portfolio of therapeutic pharmaceuticals ranging from specialty medications to generic drugs. The parent IDC enables AmerisourceBergen to supply pharmaceutical products and medical commodities to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The DLA is planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen among the critical contractors supporting these federal medical supply initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/8/25 |